Neuroimaging, both with magnetic resonance imaging (MRI) and positron emission tomography (PET), has gained a pivotal role in the diagnosis of primary @entity179 . These two techniques are used as biomarkers of both pathology and progression of @entity195 ( @entity195 ) and to differentiate @entity195 from other @entity179 . MRI is able to identify structural changes including patterns of @entity194 characterizing @entity179 , and to distinguish these from other causes of @entity73 , e.g. @entity1188 , space-occupying lesions and @entity1276 . PET is widely used to identify regional patterns of @entity413 utilization, since distinct patterns of distribution of cerebral @entity413 metabolism are related to different subtypes of neurodegenerative @entity303 . The use of PET in mild @entity73 , though controversial, is deemed helpful for predicting conversion to @entity303 and the @entity303 clinical subtype. Recently, new radiopharmaceuticals for the in vivo imaging of amyloid burden have been licensed and more tracers are being developed for the assessment of @entity13859 and inflammatory processes, which may underlie the onset of the amyloid cascade. At present, the cerebral amyloid burden, imaged with PET, may help to exclude the presence of @entity195 as well as forecast its possible onset. Finally PET imaging may be particularly useful in ongoing clinical trials for the development of @entity303 treatments. In the near future, the use of the above methods, in accordance with specific guidelines, along with the use of effective treatments will likely lead to more timely and successful treatment of @entity179 .

Magnetic resonance imaging and positron emission tomography in the diagnosis of XXXX .

@entity1276 :: ('MESH:D006849', 'Disease') :: ['hydrocephalus'] @entity13859 :: ('MESH:D024801', 'Disease') :: ['tauopathies'] @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia'] @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive impairment'] @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarcts'] @entity179 :: ('MESH:D019636', 'Disease') :: ['neurodegenerative diseases', 'neurodegenerative dementias'] @entity194 :: ('MESH:D001284', 'Disease') :: ['atrophy'] @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', "Alzheimer's disease"] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity179 :: (MESH:D019636,Disease) :: ['neurodegenerative dementias']
